Enzymit Achieves World’s First Scaled Cell-Free Production of Hyaluronic Acid
11 November 2025, Netherlands: Enzymit, a synthetic biology company pioneering cell-free biomanufacturing, in partnership with Cosun, an agricultural cooperative and leader in sustainable, circular production of plant-based ingredients, announced successful pilot-scale manufacturing at the 200-liter scale of hyaluronic acid (HA) using an enzyme-only, cell-free process. The campaign produced multi-kilogram quantities of high-purity HA, demonstrating superior process efficiency and product consistency compared with traditional fermentation.
Hyaluronic acid is among the world’s most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering. The global hyaluronic acid products market valued at $9.43B in 2025 is projected to grow to $15.94B by 2035, underscoring the urgent need for high-purity, high-performance biomaterials.
Enzymit’s cell-free process is the first to let manufacturers set the size of hyaluronic acid during production. Using the same enzymatic process, it can make HA in defined sizes from about 10 kDa to about 4 MDa with a very narrow size distribution, adjusted through standard production settings rather than changing enzymes or organisms.
“We are honored to have been a part of Enzymit’s journey in scaling their lab protocol to pilot scale, and very proud that process development and first-ever factory operation were successful based on our existing manufacturing assets. It’s exciting to see this cell-free technology become an industrial reality within such a short amount of time,” said Marie Dobenesque, Chief Technology Officer, Cosun RD&I.
This is a demonstration of Enzymit’s cell-free biomanufacturing platform utilizing AI-designed enzymes, capable of synthesizing complex bioproducts without the use of living cells – faster, cleaner, and more efficiently than ever before.
“This isn’t just a breakthrough in hyaluronic acid production – it’s a glimpse into the future of how we make molecules,” said Gideon Lapidoth, CEO of Enzymit. “By combining AI-designed enzymes with a robust cell-free system, we’ve removed biological bottlenecks and proven that precision manufacturing of biomolecules is no longer limited by what cells can or can’t do.”
Also Read: Maharashtra’s Sweet Lime Farmers Hit by 48°C Heat, Drought, and Unpaid Insurance Claims
📢 If You’re in Agriculture, Make Sure the Right People Hear Your Story.
From product launches to strategic announcements, Global Agriculture offers unmatched visibility across international agri-business markets. Connect with us at pr@global-agriculture.com to explore editorial and advertising opportunities that reach the right audience, worldwide.
